Literature DB >> 27497685

Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients.

Alliny de Souza Bastos1, Dana T Graves2, Ana Paula de Melo Loureiro3, Carlos Rossa Júnior4, Sâmia Cruz Tfaile Corbi5, Fausto Frizzera6, Raquel Mantuaneli Scarel-Caminaga5, Niels Olsen Câmara7, Oelisoa M Andriankaja8, Meire I Hiyane7, Silvana Regina Perez Orrico4.   

Abstract

BACKGROUND: The effect of the interaction between type 2 diabetes and dyslipidemia on inflammation and lipid peroxidation (LPO) has not been assessed. AIM: To investigate whether diabetes coupled with dyslipidemia alters oxidative metabolism leading to increased LPO products and inflammatory status.
METHODS: 100 patients were divided into four groups based upon diabetic and dyslipidemic status: poorly controlled diabetes with dyslipidemia (DM-PC/D), well-controlled diabetes with dyslipidemia (DM-WC/D), normoglycemic individuals with dyslipidemia (NG/D), and normoglycemic individuals without dyslipidemia (NG/ND). Plasma was evaluated for an LPO product (MDA), antioxidant levels and inflammatory cytokines.
RESULTS: Diabetics presented significantly higher levels of LPO (p<0.05) and the DM-PC/D had higher levels of proinflammatory cytokines and MDA in the plasma in comparison with normoglycemics (p<0.05). Interestingly IL1-β, IL-6, and TNF-α in DM-WC/D were not statistically different from those in DM-PC/D. Normoglycemic individuals with dyslipidemia presented significantly increased levels of IL-6 and TNF-α when compared to normoglycemic without dyslipidemia (p<0.05). MDA levels were also positively correlated with the presence of DM complications (r=0.42, p<0.01).
CONCLUSIONS: These findings show that dyslipidemia is associated with an increased inflammatory status, even in well-controlled diabetics and in normoglycemics. Our results suggest that lipid metabolism and peroxidation are important for the development of inflammation, which is elevated in several complications associated with diabetes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokines; Diabetes mellitus type 2; Dyslipidemia; Inflammation; Lipid peroxidation

Mesh:

Substances:

Year:  2016        PMID: 27497685      PMCID: PMC5120401          DOI: 10.1016/j.jdiacomp.2016.07.011

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  52 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study.

Authors:  S Mirza; Monir Hossain; Christine Mathews; Perla Martinez; Paula Pino; Jennifer L Gay; Anne Rentfro; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Cytokine       Date:  2011-10-28       Impact factor: 3.861

3.  Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.

Authors:  J C Pickup; G D Chusney; S M Thomas; D Burt
Journal:  Life Sci       Date:  2000-06-08       Impact factor: 5.037

Review 4.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.

Authors:  Brent E Wisse
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

Review 5.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

6.  Protein oxidation biomarkers in plasma of type 2 diabetic patients.

Authors:  Kanti Bhooshan Pandey; Neetu Mishra; Syed Ibrahim Rizvi
Journal:  Clin Biochem       Date:  2009-11-23       Impact factor: 3.281

7.  Total plasma malondialdehyde levels in 16 Taiwanese college students determined by various thiobarbituric acid tests and an improved high-performance liquid chromatography-based method.

Authors:  Y L Hong; S L Yeh; C Y Chang; M L Hu
Journal:  Clin Biochem       Date:  2000-11       Impact factor: 3.281

8.  Glycaemic status in relation to oxidative stress and inflammation in well-controlled type 2 diabetes subjects.

Authors:  Elisabet Rytter; Bengt Vessby; Rikard Asgård; Clara Johansson; Anders Sjödin; Lilianne Abramsson-Zetterberg; Lennart Möller; Samar Basu
Journal:  Br J Nutr       Date:  2009-05       Impact factor: 3.718

Review 9.  The metabolic basis of atherogenic dyslipidemia.

Authors:  Aaron I Vinik
Journal:  Clin Cornerstone       Date:  2005

Review 10.  Diabetic dyslipidemia.

Authors:  R A Kreisberg
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778

View more
  21 in total

Review 1.  "Inflammatory skin march" in atopic dermatitis and psoriasis.

Authors:  Masutaka Furue; Takafumi Kadono
Journal:  Inflamm Res       Date:  2017-06-15       Impact factor: 4.575

Review 2.  Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease.

Authors:  Joshua A Kulas; Thaddeus K Weigel; Heather A Ferris
Journal:  Drug Dev Res       Date:  2020-02-05       Impact factor: 4.360

3.  Mechanisms Underlying Early-Stage Changes in Visual Performance and Retina Function After Experimental Induction of Sustained Dyslipidemia.

Authors:  Christa L Montgomery; Heather M Johnson; Thomas P Johnston; Peter Koulen
Journal:  Neurochem Res       Date:  2018-06-02       Impact factor: 3.996

4.  Expression Profile of Genes Potentially Associated with Adequate Glycemic Control in Patients with Type 2 Diabetes Mellitus.

Authors:  Sâmia Cruz Tfaile Corbi; Alliny Souza Bastos; Rafael Nepomuceno; Thamiris Cirelli; Raquel Alves Dos Santos; Catarina Satie Takahashi; Cristiane S Rocha; Silvana Regina Perez Orrico; Claudia V Maurer-Morelli; Raquel Mantuaneli Scarel-Caminaga
Journal:  J Diabetes Res       Date:  2017-07-25       Impact factor: 4.011

5.  Dyslipidemia rather than Type 2 Diabetes Mellitus or Chronic Periodontitis Affects the Systemic Expression of Pro- and Anti-Inflammatory Genes.

Authors:  Rafael Nepomuceno; Bárbara Scoralick Villela; Sâmia Cruz Tfaile Corbi; Alliny De Souza Bastos; Raquel Alves Dos Santos; Catarina Satie Takahashi; Silvana Regina Perez Orrico; Raquel Mantuaneli Scarel-Caminaga
Journal:  Mediators Inflamm       Date:  2017-02-20       Impact factor: 4.711

6.  Data-Driven Cluster Analysis of Oxidative Stress Indexes in relation to Vitamin D Level, Age, and Metabolic Control in Patients with Type 2 Diabetes on Metformin Therapy.

Authors:  Milena M Cojic; Aleksandra Klisic; Radivoj Kocic; Andrej Veljkovic; Gordana Kocic
Journal:  Oxid Med Cell Longev       Date:  2021-06-21       Impact factor: 6.543

7.  Effect of combined gliclazide/metformin treatment on oxidative stress, lipid profile, and hepatorenal functions in type 2 diabetic patients.

Authors:  Mansour Alsharidah; Metab Algeffari; Abdel-Moneim Hafez Abdel-Moneim; Mohamed Faisal Lutfi; Haila Alshelowi
Journal:  Saudi Pharm J       Date:  2017-11-14       Impact factor: 4.330

Review 8.  Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.

Authors:  Masutaka Furue; Gaku Tsuji; Takahito Chiba; Takafumi Kadono
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

9.  Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE.

Authors:  Foo Nian Wong; Kek Heng Chua; Jin Ai Mary Anne Tan; Chew Ming Wong; Umah Rani Kuppusamy
Journal:  PeerJ       Date:  2018-03-30       Impact factor: 2.984

Review 10.  Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies?

Authors:  Dominique Lombardo; Françoise Silvy; Isabelle Crenon; Emmanuelle Martinez; Aurélie Collignon; Evelyne Beraud; Eric Mas
Journal:  Oncotarget       Date:  2017-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.